Clinical pathways for doctors in Pakistan

These are not summaries of ADA, NICE or IDSA — those already exist, and they are better than anything we would write. What these pathways show is where Pakistani practice has to diverge from them, and why: national guideline adaptations, drugs that are not available here, and local resistance data that makes the standard empiric choice the wrong one.

Every recommendation carries a divergence badge

Same as international guideline No local modification — the international recommendation applies here unchanged.

Pakistan-adapted A national body has deliberately changed this for Pakistani conditions, or availability and cost force a different choice. The reason is always stated.

Local data only No national guideline covers this. The recommendation rests on published Pakistani surveillance or cohort data, cited so you can weigh it.

National guideline outdated A Pakistani guideline exists but predates the evidence that now matters — most often because resistance has moved since it was written.

Free

Tuberculosis

The only place a national programme tells WHO no — twice. Plus why BPaLM is standard on paper but not everywhere in practice, and why 24% of TB patients turn out to be diabetic.

Built on: National Strategic Plan 2024–26 · PMDT 2020 · NTP 2024 paediatric updates

🔬 Beta — pending clinical sign-off

Open →

Free

Hepatitis C

The world's largest burden, a national programme built for non-specialists, and generic drugs curing 98%. No biopsy needed — includes a working FIB-4 calculator and the rifampicin, PPI and amiodarone interactions.

Built on: National Consensus Practice Guidelines (PSG, PSH, STEP) · PM's Elimination Programme